Bayer

Bayer’s strongest-ever pharma portfolio and promising pipeline drive future growth

02 Apr 2026

AskBio Announces Completion of Enrollment in Phase 2 Clinical Trial of AB-1002 Investigational Gene Therapy for Heart Failure

02 Apr 2026

Kerendia™ approved in EU for new indication in adult patients with heart failure with LVEF ≥40%

02 Apr 2026

Eylea™ 8 mg approved for third retinal indication in Japan

23 Mar 2026

First approval for Bayer’s low-dose MRI contrast agent in Japan

23 Mar 2026

Finerenone meets primary endpoint in pivotal Phase III FIND-CKD study in patients with non-diabetic chronic kidney disease

23 Mar 2026

Missouri court grants preliminary approval of Roundup™ class settlement to resolve current and future claims

05 Mar 2026

Financial News Conference on the Full Year 2025 Results

04 Mar 2026

Bayer delivers upgraded 2025 ambition, projects solid 2026, focused on strategic priorities

04 Mar 2026

Bayer reports encouraging results for next generation investigational targeted radionuclide therapy 225Ac-PSMA-Trillium in advanced metastatic prostate cancer

27 Feb 2026

View details about the software product Informachine News Trackers